About: Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
Creator	Kim, Chul Addeo, Alfredo Banna, Giuseppe Friedlaender, Alex Hendriks, Lizza Menis, Jessica Veneto, Istituto
source	Medline; PMC
abstract	Immune checkpoint inhibitors (ICPIs) have revolutionized the management and prognosis of fit patients with advanced non-small cell lung cancer (NSCLC). Recently, the publication of 5-year survival rates has cemented the role of ICPIs in NSCLC. An ongoing challenge is to determine the optimal treatment duration to find the balance between efficacy, toxicity and cost. From the onset of ICPI trials, different durations were used, ranging from treatment until progression or toxicity, to fixed durations of 2 years. Subsequently, exploratory analyses from a 1-year fixed duration trial failed to change practice. There are, to date, no adequately powered prospective trials addressing this important question. With today's severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) pandemic, more than ever, the question resurfaces with added factors tilting the already shaky therapeutic balance. Here, we will discuss current data regarding ICPI treatment duration and incorporate this into the context of the ongoing pandemic. We conclude with a discussion of pragmatic approaches, should physicians be unable to continue standard therapy.
has issue date	2020-05-12(xsd:dateTime)
bibo:doi	10.3389/fonc.2020.00862
bibo:pmid	32574277
has license	cc-by
sha1sum (hex)	c937c633b09cea76967a31e393e5948658802605
schema:url	https://doi.org/10.3389/fonc.2020.00862
resource representing a document's title	Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
has PubMed Central identifier	PMC7239024
has PubMed identifier	32574277
schema:publication	Front Oncol
resource representing a document's body	covid:c937c633b09cea76967a31e393e5948658802605#body_text
is schema:about of	named entity 'advanced' named entity 'efficacy' named entity 'factors' named entity 'determine' named entity 'continue' named entity 'therapy' named entity 'failed' named entity 'patients' named entity 'data' named entity 'inhibitors' named entity 'fixed' named entity 'optimal' named entity 'context' named entity 'ongoing' named entity 'balance' named entity 'NSCLC' named entity 'ICPI' named entity '5-year survival' named entity 'ICPI' named entity 'Immune checkpoint inhibitors' named entity 'ctDNA' named entity 'nivolumab' named entity 'infection' named entity 'toxicity' named entity 'chemotherapy' named entity 'ICPI' named entity 'long-term' named entity 'thoracic cancer' named entity 'Prognostic' named entity 'long-term' named entity 'adverse events' named entity 'COVID' named entity 'half-life' named entity 'long-term' named entity 'anti-PD-1' named entity 'hazard ratio' named entity 'phase II' named entity 'specific cancer treatment' named entity 'toxicity' named entity 'ECOG performance status' named entity 'radiographical' named entity 'nivolumab' named entity 'toxicity' named entity 'nivolumab' named entity 'ICPI' named entity 'atezolizumab' named entity 'NSCLC' named entity 'anti-PD-1' named entity 'antitumor' named entity 'rechallenge' named entity 'adverse events' named entity 'virus' named entity 'ICPI' named entity 'SARS-COV-2' named entity 'risk factors' named entity 'median follow-up' named entity 'lung cancer' named entity 'ICPI' named entity 'NSCLC' named entity 'performance status' named entity '10.3' named entity 'ICPI' named entity 'Immune checkpoint inhibitors' named entity 'PD-1' named entity 'nivolumab' named entity '18.2' named entity 'United States' named entity 'pembrolizumab' named entity 'melanoma' named entity 'SARS-CoV-2' named entity 'oncologist' named entity 'retrospective study' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'cohort study' named entity 'coronavirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software